Abstract 1778P
Background
In the phase 3 EMBARK trial, after a median follow-up of 60.7 months, enza + LA (HR 0.42; 95% CI, 0.30–0.61; p<0.0001) and enza monotherapy (HR 0.63; 95% CI, 0.46–0.87; p=0.0049) demonstrated statistically superior and clinically meaningful improvements in metastasis-free survival vs placebo (pbo) + LA. Here, we present other non-key secondary efficacy endpoints for enza + LA vs pbo + LA.
Methods
EMBARK (NCT02319837) is a study of patients (pts) with high-risk biochemical recurrence (BCR): prostate-specific antigen (PSA) doubling time ≤9 months and PSA ≥2 ng/mL above nadir post-radiotherapy (RT) or ≥1 ng/mL after radical prostatectomy ± postoperative RT. Pts were double-blinded and randomized (1:1) to enza 160 mg/day + LA or pbo + LA (LA alone). LA 22.5 mg was administered every 12 weeks. If the PSA at Week 36 was <0.2 ng/mL, tx was suspended at Week 37 and restarted when PSA was ≥2 ng/mL for pts with primary RP, and ≥5 ng/mL for pts without RP. Secondary endpoints included time to: distant metastasis, resumption of any hormonal therapy after tx suspension, castration resistance, symptomatic progression, and first symptomatic skeletal event.
Results
713 pts were eligible and randomized into the study (enza + LA, n=355; LA alone, n=358). Median (range) tx duration excluding tx suspension was 32.4 (0.1–83.4) months for enza + LA and 35.4 (0.7–85.7) months for LA alone. Time to: distant metastasis (HR 0.44; 95% CI, 0.28–0.69; p=0.0002), resumption of any hormonal therapy after tx suspension (HR 0.69; 95% CI, 0.58–0.83; p<0.0001), castration resistance (HR 0.09; 95% CI, 0.05–0.16; p<0.0001), symptomatic progression (HR 0.55; 95% CI, 0.43–0.70; p<0.0001), and first symptomatic skeletal event (HR 0.26; 95% CI, 0.13–0.55; p=0.0001) favored enza + LA vs LA alone. All p-values are nominal.
Conclusions
In pts with high-risk BCR, enza + LA vs LA alone demonstrated clinically meaningful delays in time to: distant metastasis, resumption of any hormonal therapy after tx suspension, castration resistance, symptomatic progression, and first symptomatic skeletal event. If approved, enza combination may represent a new standard of care for pts with high-risk BCR.
Clinical trial identification
NCT02319837.
Editorial acknowledgement
Medical writing and editorial support were provided by Isabel Aitcheson, BSc, and Sinead Stewart, of Onyx (a Prime Global agency) funded by Pfizer, Inc. and Astellas Pharma, Inc., co-developers of enzalutamide.
Legal entity responsible for the study
Pfizer, Inc. and Astellas Pharma, Inc.
Funding
Pfizer, Inc. and Astellas Pharma, Inc.
Disclosure
S.J. Freedland: Financial Interests, Institutional, Speaker, Consultant, Advisor: Astellas Pharma Inc., Pfizer, Janssen, Bayer, Sanofi, Dendreon, Myovant, AstraZeneca, Merck. M.E. Gleave: Financial Interests, Institutional, Stocks or ownership: OncoGenex Technologies, Sustained Therapeutics, Sitka Pharmaceuticals; Financial Interests, Institutional, Speaker, Consultant, Advisor: Astellas Pharma Inc., AstraZeneca, Bayer, GDx, Janssen, Sanofi, Pfizer, TerSera, Roche; Financial Interests, Institutional, Other, Holds patents for OGX-011: OGX-011; Financial Interests, Institutional, Other, Holds patents for OGX-427: OGX-427; Financial Interests, Institutional, Other, Holds patents for ST-CP: ST-CP; Financial Interests, Institutional, Other, Holds patents for ST-POP: ST-POP. U.F.F. De Giorgi: Financial Interests, Institutional, Speaker, Consultant, Advisor: Astellas Pharma Inc., Bayer, BMS, Ipsen, Janssen, Novartis, Pfizer, Sanofi, PharmaMar; Financial Interests, Institutional, Research Funding: AstraZeneca, Roche, Sanofi; Financial Interests, Personal, Funding, Travel funds: BMS, Ipsen, Janssen, Pfizer, Roche. A. Rannikko: Financial Interests, Institutional, Advisory Board: Bayer, Janssen, Orion Pharma; Financial Interests, Institutional, Leadership Role, Board chair: Orion Research Foundation; Financial Interests, Institutional, Member of Board of Directors: Ida Montin Research Foundation. C. Pieczonka: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Bayer, Blue Earth, CellVax, Dendreon, Eli Lilly, Janssen, Merck, Myovant Sciences, Pfizer, Daiichi Sankyo, Sun; Financial Interests, Institutional, Other, Honoraria: AstraZeneca, Bayer, Dendreon, Janssen, Merck, Myovant Sciences, Sun; Financial Interests, Institutional, Other, Honoraria; received equipment, materials, drugs, medical writing, gifts or other services: Astellas Pharma Inc., Pfizer. K. Brasso: Financial Interests, Institutional, Speaker, Consultant, Advisor: Astellas Pharma Inc., Bayer, Janssen, Merck Sharp & Dohme, Novartis. H. Woo: Financial Interests, Institutional, Speaker, Consultant, Advisor, Consultant and shareholder: Prospection Party Ltd; Financial Interests, Institutional, Advisory Board, Advisory board member and has received honoraria: Astellas Pharma Inc.; Financial Interests, Institutional, Other: Bayer, Boston Scientific, Cipla, Janssen; Financial Interests, Institutional, Member of Board of Directors: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australasian Urological Foundation, Australasian College of Surgeons, Urological Society of Australia and New Zealand. A. Gomez Caamaño: Financial Interests, Institutional, Speaker, Consultant, Advisor: Astellas Pharma Inc., Bayer, Janssen; Financial Interests, Institutional, Funding, Institutional funding: Astellas Pharma Inc.; Financial Interests, Institutional, Other, Honoraria: Astellas Pharma Inc., AstraZeneca, Bayer, Janssen; Financial Interests, Personal, Other, Travel expenses: Astellas Pharma Inc., Bayer, Janssen. Y. Tang, B. Rosbrook, F. Zohren: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. G.P. Haas, M. Rosales: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma, Inc.; Financial Interests, Personal, Stocks/Shares: Astellas Pharma, Inc.. N.D. Shore: Financial Interests, Institutional, Research Funding: AbbVie, Amgen, Astellas Pharma Inc., AstraZeneca, Bayer, BMS, Dendreon, Exact Sciences, Ferring, FerGene, Janssen, MDx Health, Merck, Myovant, Nymox, Pfizer, Sanofi, Tolmar. All other authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14